Skip to main content
. 2021 Dec 8;7(3):e002038. doi: 10.1136/rmdopen-2021-002038

Figure 1.

Figure 1

Cumulative distribution of structural progression across patients treated with infliximab (INF) or placebo (PLC). Only 2.8 % of patients randomised to INF progressed >1 in modified Sharp/van-der-Heijde score (mTSS), whereas 17.6 % progressed in the PLC arm (p=0.004).